-
公开(公告)号：EP1373433B1
公开(公告)日：2008-07-23
申请号：EP02707815.3
申请日：2002-02-20
IPC分类号： C09K19/00
CPC分类号： C09K19/54 , C09K19/00 , C09K2019/528
-
公开(公告)号：EP1664294A2
公开(公告)日：2006-06-07
申请号：EP04809768.7
申请日：2004-09-17
IPC分类号： C12N15/00 , G01N33/50 , A01K67/027 , C12N15/85 , C12N9/12
CPC分类号： C12N15/8509 , A01K67/0275 , A01K67/0276 , A01K2217/05 , A01K2217/072 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0375 , A61K38/00 , C07K14/4702 , C07K2319/60 , C12N9/1205 , C12N2799/022 , C12N2830/008
摘要： The methods and compositions of the present invention find use in altering expression of PKCalpha in transgenic animals. The compositions of the invention include isolated transgenic animal cells, transgenic tissue, and transgenic mice. The transgenic animals of the invention exhibit altered PKCalpha activity. The methods allow generation of transgenic animals with altered expression of PKCalpha. The invention allows modulation of cardiac contractility. In particular, the invention provides a method for altering the susceptibility of a transgenic animal to cardiomyopathy. A transgenic animal of the invention finds use in identifying anti-cardiomyopathic compounds.
-
公开(公告)号：EP1630168A2
公开(公告)日：2006-03-01
申请号：EP05077575.8
申请日：1998-08-26
发明人： Granoff, Dan M. , Moe, Gregory R.
IPC分类号： C07K5/06 , C07K5/08 , C07K14/22 , C07K16/12 , G01N33/569
CPC分类号： C07K5/0207 , A61K39/00 , C07K5/06026 , C07K5/06139 , C07K5/0806 , C07K14/22 , C07K16/1221 , G01N33/56911 , G01N2333/22 , G01N2333/245 , G01N2469/20 , Y10S436/811
摘要： Molecular mimetics of unique epitopes of Neisseria meningitidis serogroup B ("MenB") are disclosed. Compositions containing such molecular mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody responses.
摘要翻译： 披露了脑膜炎奈瑟氏球菌血清群B（“MenB”）独特表位的分子模拟物。 含有此类分子模拟物的组合物可用于预防MenB或大肠杆菌K1疾病，而不会引起自身抗体反应。
-
54.发明公开USE OF FGF- 18 PROTEIN, TARGET PROTEINS AND THEIR RESPECTIVE ENCODING NUCLEOTIDE SEQUENCES TO INDUCE CARTILAGE FORMATION 审中-公开FGF-18蛋白，靶蛋白及其各编码核苷酸序列期感应软骨形成的用途
公开(公告)号：EP1613267A2
公开(公告)日：2006-01-11
申请号：EP04758380.2
申请日：2004-03-26
IPC分类号： A61K6/00
CPC分类号： A61K38/1825 , A01K67/0275 , A01K67/0276 , A01K2217/052 , A01K2217/077 , A01K2217/15 , A01K2217/203 , A01K2227/105 , A01K2267/03 , A61K38/1709 , A61K38/177 , A61K38/18 , A61K38/1841 , A61K38/1875 , A61K48/00 , C07K14/46 , C07K14/50 , Y02A50/411 , A61K2300/00
摘要： The use of fibroblast growth factor (FGF)-18 protein, certain of its downstream target genes and respective expressed proteins, in particular sonic hedgehog (Shh), Shh protein, &bgr;-catenin, &bgr;-catenin protein, and the Wnt family of proteins that stimulate &bgr;-catenin, and the respective nucleotide sequences encoding this protein, particularly for inducing cartilage formation, particularly for the purpose of generating, repairing, reconstructing, or de novo formation of, cartilaginous tissue. Therapies for which FGF-18 and the target proteins are useful include repair and reconstruction of various tissues in conducting airways such as the trachea, bronchi, lung and larynx caused by, for example, tracheal-bronchial abnormalities, tracheal-laryngo or bronchial malaria. Other therapies for which FGF-18 and the target proteins would be useful include other cartilaginous tissues, such as those of joint and skeletal tissue caused by, for example, arthritis and meniscus abnormalities in joints.
-
55.发明公开
公开(公告)号：EP1551857A2
公开(公告)日：2005-07-13
申请号：EP03763196.7
申请日：2003-07-03
发明人： ROBBINS, Jeffrey
CPC分类号： A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , C12N15/85 , C12N15/8509 , C12N2830/003 , C12N2830/008 , C12N2830/85
摘要： The methods and compositions of the present invention find use in altering cardiac-preferred expression in transgenic animals. The compositions of the invention include isolated nucleic acid molecules, expression cassettes, animal cells, transgenic animals, and transgenic mice. The transgenic animals of the invention exhibit inducible cardiac preferred expression of a nucleotide sequence of interest. The methods allow generation of transgenic animals with altered cardiac preferred expression of the nucleotide sequence of interest. In particular, the invention provides a method for altering the susceptibility of a transgenic animal to cardiopathy. A transgenic animal of the invention finds use in identifying anti-cardiopathic compounds.
-
公开(公告)号：EP1545661A2
公开(公告)日：2005-06-29
申请号：EP03770315.4
申请日：2003-09-12
发明人： WALL, Eric, James
CPC分类号： A61M5/422 , A61K9/0019 , A61K9/0021 , A61M5/14248 , A61M5/14526 , A61M5/1454 , A61M5/14586 , A61M5/1782 , A61M5/2033 , A61M5/2046 , A61M5/2053 , A61M5/282 , A61M5/3257 , A61M5/326 , A61M5/46 , A61M2005/14252 , A61M2005/1426 , A61M2005/206 , A61M2005/2073
摘要： A device for painlessly injecting medications, and a method for providing a substantially painless injection of medication into a patient that does not require the use of an anesthetic, that does not require the medical personnel to spend a substantial amount of time performing the infection procedure, that is relatively simple and inexpensive to perform and operate, and that provides a relatively high degree of safety for both the medical personnel and for the patient. The injection needle (40) can have an outside diameter greater than 0.20 mm and less than about 0.38 mm. The medicament can be injected painlessly through the needle and into the patient at a substantially constant volumetric flow rate of about 0.05 gL/s to about 50 gL/s.
-
57.发明公开
公开(公告)号：EP1501475A1
公开(公告)日：2005-02-02
申请号：EP03724369.8
申请日：2003-05-02
CPC分类号： A61Q19/007 , A61K8/11 , A61K8/14 , A61K8/982 , A61K8/985 , A61K2800/413 , A61Q17/00 , A61Q19/00
摘要： A composition and a method of producing a composition which simulates hydration, cleansing and other properties of native vernix. The composition contains hydrated synthetic cells in a lipid matrix to provide rheological properties which are substantially similar to those of native vernix, and may also contain proteins. In one embodiment, the composition contains cubosomes/water with up to 30 % protein and about 5 % lipid to about 30 % lipid. The composition may be used to cleanse newborn skin, compromised skin surfaces, as well as normal skin, to provide hydration/barrier function, and other applications.
-
公开(公告)号：EP0607301B2
公开(公告)日：2004-12-08
申请号：EP92921805.5
申请日：1992-10-06
发明人： KITAEVICH, Yuli , HEMASILPIN, Nat , MARCHEVSKY, J., Gabriel , BISSLER, John, J. , BENZING, George, III , McENERY, Paul, T.
IPC分类号： A61M1/16
CPC分类号： A61M1/16 , A61M1/1643 , A61M1/34 , A61M1/341 , A61M1/3427 , A61M1/3451 , A61M1/3607 , A61M2205/15 , A61M2205/3331 , A61M2205/3334 , A61M2205/3344 , A61M2205/3368 , A61M2205/3393 , A61M2205/50 , Y10S210/929
-
59.发明公开
公开(公告)号：EP1448056A2
公开(公告)日：2004-08-25
申请号：EP02795581.4
申请日：2002-10-30
CPC分类号： A01K67/0275 , A01K67/0276 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0337 , A01K2267/0368 , A61K38/00 , C07K14/4726 , C07K14/785 , C12N15/8509
摘要： Surfactant protein D (SP-D) is a 43-kDa member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. The SP-D gene was targeted by homologous recombination in embryonic stem cells that were used to produce SP-D (-/-) mice. The SP-D (-/-) deficiency caused inflammation, increased oxidant production by isolated alveolar macrophages, abnormal surfactant structure and levels, and decreased SP-A expression. Therefore, disclosed is the SP-D (-/-) mouse as an excellent model for emphysema. Also included are models for testing emphysema therapies in the mouse model, methods for using SP-D protein or DNA as a treatment for emphysema and pulmonary infections, and diagnosis.
-
60.发明授权MONOCLONAL ANTIBODIES THAT DEFINE UNIQUE MENINGOCOCCAL B EPITOPES AND THEIR USE IN THE PREPARATION OF VACCINE COMPOSITIONS 失效脑膜炎球菌B-表位形成的单克隆抗体及其使用疫苗组合物的制造
公开(公告)号：EP0922059B1
公开(公告)日：2003-10-22
申请号：EP97941371.3
申请日：1997-08-27
发明人： GRANOFF, Dan , MOE, Gregory, R.
CPC分类号： C07K14/22 , A61K39/00 , A61K2039/505 , C07K16/1217 , C07K2317/34 , G01N33/56911 , G01N2333/22 , Y10S514/898 , Y10S530/807 , Y10S530/808
摘要： Novel bactericidal antibodies against Neisseria meningitidis serogroup B ('MenB') are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are used to identify molecular mimetics of unique eptitopes found on MenB or E. coli K1. Examples of such peptide mimetics are described that elicit serum antibody capable of activating complement-mediated bacteriolysis of MenB. Vaccine compositions containing such mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody.
-
-
-
-
-
-
-
-
-
搜索结果
360 条记录 (耗时 0.027 秒)
